The HDACi vorinostat is clinically approved for the treatment of cutaneous T-cell lymphoma and has modest single-agent activity in advanced AML and myelodysplastic syndrome [43] and limited activity in EWS [10, 19]. The gene discussed is EWSR1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.